Drug Type Molecular glue |
Synonyms CDK2 bivalent degrader(Plexium) |
Target |
Mechanism CDK2 modulators(Cyclin-dependent kinase 2 modulators), CRBN inhibitors(Cereblon inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Plexium, Inc.Startup |
Active Organization Plexium, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | US | Plexium, Inc.Startup | 08 Jun 2024 |
Endometrial Carcinoma | Preclinical | US | Plexium, Inc.Startup | 08 Jun 2024 |
Ovarian Cancer | Preclinical | US | Plexium, Inc.Startup | 08 Jun 2024 |
ER-positive/HER2-negative Breast Cancer | Discovery | US | Plexium, Inc.Startup | 05 Jan 2024 |